Related Experiment Videos
[Repaglinide, potentially a therapeutic improvement for diabetes mellitus type 2]
1Universitair Medisch Centrum, Julius Centrum voor Huisartsgeneeskunde en Patiëntgebonden Onderzoek, Postbus 85.060, 3508 AB Utrecht. g.e.h.m.rutten@med.uu.nl
Abstract:
In about 25% of type 2 diabetes patients, good diabetes control is not attainable with oral blood-glucose lowering drugs. Furthermore, in many people with diabetes the disease deteriorates, despite the use of blood-glucose lowering medication, due to the decline of the pancreatic beta cells. The development of new drugs, such as repaglinide, is therefore important. Repaglinide is an insulin secretion enhancer with a different mechanism of action to the sulphonylureas, which means it does not continuously stimulate insulin secretion. The tablets should be taken with each meal. After oral ingestion repaglinide is resorbed quickly, with a half-life of between 30 minutes to an hour. In clinical trials repaglinide has been found to be equally effective as glibenclamide. Repaglinide has been found to be particularly effective in sulphonylurea-naïve patients. Skipping the meal plus tablet combination results in less frequent hypoglycaemic symptoms compared to glibenclamide. Repaglinide results in greater reductions in postprandial glucose levels than glibenclamide. It does not affect insulin resistance. Long-term data are lacking, both with regard to efficacy and side effects. Repaglinide deserves a place in the diabetes treatment of newly-diagnosed type 2 diabetes patients who are well-informed about their disease, as well as in patients with renal failure. It should also be considered for patients whose diabetes is poorly controlled on metformin monotherapy.
Insights
Repaglinide offers an effective treatment option for type 2 diabetes when oral medications fail. This insulin secretion enhancer provides better post-meal glucose control with fewer side effects like hypoglycemia.
Area of Science:
- Pharmacology
- Endocrinology
- Metabolic Diseases
Background:
- Type 2 diabetes often requires medication beyond oral agents for adequate glycemic control.
- Pancreatic beta-cell decline can lead to disease progression despite existing treatments.
- Newer antidiabetic agents are crucial for managing type 2 diabetes effectively.
Purpose of the Study:
- To evaluate the efficacy and safety of repaglinide as a treatment for type 2 diabetes.
- To compare repaglinide's effectiveness against existing oral hypoglycemic agents.
- To identify patient populations who may benefit most from repaglinide therapy.
Main Methods:
- Clinical trials were conducted to assess repaglinide's efficacy.
- Repaglinide's effectiveness was compared to glibenclamide, a standard treatment.
- Pharmacokinetic properties, including absorption and half-life, were analyzed.
Main Results:
- Repaglinide demonstrated comparable efficacy to glibenclamide in clinical trials.
- Repaglinide significantly reduced postprandial glucose levels more effectively than glibenclamide.
- Fewer hypoglycemic symptoms were reported with repaglinide, especially when meals were skipped.
Conclusions:
- Repaglinide is a valuable therapeutic option for type 2 diabetes, particularly for newly diagnosed patients and those with renal impairment.
- It offers an alternative for patients inadequately controlled on metformin monotherapy.
- Further long-term studies are needed to fully assess repaglinide's efficacy and safety profile.